|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TCEA3 |
Gene summary for TCEA3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TCEA3 | Gene ID | 6920 |
| Gene name | transcription elongation factor A3 | |
| Gene Alias | TFIIS | |
| Cytomap | 1p36.12 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | B4DUM4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6920 | TCEA3 | GSM4909281 | Human | Breast | IDC | 1.58e-03 | 1.64e-01 | 0.21 |
| 6920 | TCEA3 | GSM4909282 | Human | Breast | IDC | 2.34e-12 | 4.53e-01 | -0.0288 |
| 6920 | TCEA3 | GSM4909290 | Human | Breast | IDC | 1.48e-03 | 3.19e-01 | 0.2096 |
| 6920 | TCEA3 | GSM4909294 | Human | Breast | IDC | 7.21e-04 | 3.32e-01 | 0.2022 |
| 6920 | TCEA3 | GSM4909296 | Human | Breast | IDC | 6.80e-04 | 2.87e-01 | 0.1524 |
| 6920 | TCEA3 | GSM4909298 | Human | Breast | IDC | 7.15e-18 | 4.05e-01 | 0.1551 |
| 6920 | TCEA3 | GSM4909301 | Human | Breast | IDC | 4.23e-05 | 2.44e-01 | 0.1577 |
| 6920 | TCEA3 | GSM4909304 | Human | Breast | IDC | 6.63e-12 | 2.73e-01 | 0.1636 |
| 6920 | TCEA3 | GSM4909306 | Human | Breast | IDC | 5.25e-03 | 2.56e-01 | 0.1564 |
| 6920 | TCEA3 | GSM4909308 | Human | Breast | IDC | 2.12e-10 | 3.99e-01 | 0.158 |
| 6920 | TCEA3 | GSM4909311 | Human | Breast | IDC | 6.12e-05 | 8.28e-02 | 0.1534 |
| 6920 | TCEA3 | GSM4909312 | Human | Breast | IDC | 1.78e-03 | 3.02e-01 | 0.1552 |
| 6920 | TCEA3 | GSM4909315 | Human | Breast | IDC | 4.63e-10 | 4.23e-01 | 0.21 |
| 6920 | TCEA3 | GSM4909316 | Human | Breast | IDC | 1.46e-03 | 5.05e-01 | 0.21 |
| 6920 | TCEA3 | GSM4909319 | Human | Breast | IDC | 4.53e-09 | 2.24e-01 | 0.1563 |
| 6920 | TCEA3 | GSM4909321 | Human | Breast | IDC | 4.08e-05 | 2.66e-01 | 0.1559 |
| 6920 | TCEA3 | M1 | Human | Breast | IDC | 6.08e-04 | 3.02e-01 | 0.1577 |
| 6920 | TCEA3 | M5 | Human | Breast | IDC | 1.10e-02 | 5.56e-01 | 0.1598 |
| 6920 | TCEA3 | DCIS2 | Human | Breast | DCIS | 3.52e-29 | 1.44e-01 | 0.0085 |
| 6920 | TCEA3 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.49e-03 | 4.34e-01 | -0.1808 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TCEA3 | SNV | Missense_Mutation | c.269G>T | p.Gly90Val | p.G90V | O75764 | protein_coding | tolerated(0.09) | benign(0.001) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| TCEA3 | SNV | Missense_Mutation | rs551455715 | c.760C>T | p.Arg254Trp | p.R254W | O75764 | protein_coding | deleterious(0) | possibly_damaging(0.708) | TCGA-CK-4950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folfox | SD |
| TCEA3 | SNV | Missense_Mutation | rs549062868 | c.715C>T | p.Arg239Cys | p.R239C | O75764 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-F4-6856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | CR |
| TCEA3 | SNV | Missense_Mutation | novel | c.163N>A | p.Val55Ile | p.V55I | O75764 | protein_coding | tolerated(0.73) | benign(0.042) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TCEA3 | SNV | Missense_Mutation | rs774600357 | c.362N>A | p.Arg121Gln | p.R121Q | O75764 | protein_coding | tolerated(0.12) | benign(0) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TCEA3 | SNV | Missense_Mutation | rs551455715 | c.760C>T | p.Arg254Trp | p.R254W | O75764 | protein_coding | deleterious(0) | possibly_damaging(0.708) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| TCEA3 | SNV | Missense_Mutation | rs763442834 | c.761N>A | p.Arg254Gln | p.R254Q | O75764 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TCEA3 | SNV | Missense_Mutation | c.976N>T | p.Arg326Cys | p.R326C | O75764 | protein_coding | deleterious(0) | benign(0.351) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TCEA3 | SNV | Missense_Mutation | rs777318907 | c.812C>T | p.Thr271Met | p.T271M | O75764 | protein_coding | deleterious(0.03) | benign(0.378) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| TCEA3 | SNV | Missense_Mutation | c.772C>T | p.Leu258Phe | p.L258F | O75764 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |